Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus SCANLUX 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus SCANLUX 370.
CHOLOGRAFIN SODIUM vs SCANLUX-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodipamide (cholografin sodium) is a radiographic contrast agent that opacifies the biliary ducts and gallbladder by being excreted into bile via the hepatic organic anion transporter (OATP) and then concentrated in the gallbladder. It absorbs X-rays due to its iodine content, allowing visualization of the biliary tree.
Radiopaque contrast agent that contains iodine, attenuates X-rays, enhancing vascular and tissue visualization during imaging.
2-3 mL of 30% solution intravenously over 1-2 minutes, repeated if necessary up to a total of 10 mL.
The typical adult dose of SCANLUX-370 is 0.1 mg/kg administered intravenously as a single dose, up to a maximum of 7 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In severe renal impairment (CrCl < 30 mL/min), half-life may extend to 10-20 hours, requiring dose adjustment.
The terminal elimination half-life of SCANLUX-370 is approximately 1.5-2 hours in patients with normal renal function. This short half-life allows for rapid clearance and minimal accumulation with repeated dosing.
Primarily renal excretion via glomerular filtration and tubular secretion. Approximately 70-80% of the dose is excreted unchanged in urine within 24 hours. Biliary excretion accounts for less than 10%, with fecal elimination minimal.
SCANLUX-370 is primarily eliminated via renal excretion, with approximately 85-90% of the dose recovered unchanged in urine within 24 hours. The remaining 10-15% is excreted unchanged in feces via biliary elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent